conclusions an appreciable dose-concentration-response relationship between nn1731 and f 1+2 was...
TRANSCRIPT
ConclusionsAn appreciable dose-concentration-response relationship between NN1731 and F1+2 was expressed in a population PK/PD model. Since F1+2 appearance traces the formation of thrombin, this relationship supports the possibility of using F1+2 as a biomarker for haemostatic agents.
Aims To explore the potential of prothrombin fragments 1&2 (F1+2) as a biomarker for haemostatic agents with a model of the effects of the FVIIa analogue NN1731.
BackgroundHaemophilic patients suffer a defect in blood coagulation due to lack of either coagulation factor VIII or IX. In some patients, replacement therapy with the lacking coagulation factor eventually results in the formation of antibodies (inhibitors). Inhibitor patients may be treated with by-passing agents such as activated human coagulation factor FVII (FVIIa, NovoSeven). NN1731 is a FVIIa analogue that in vitro has shown increased activity in stimulating the cleavage of prothrombin to thrombin and F1+2, a key step in the coagulatory
pathway1. F1+2 was measured in the first clinical trial with NN1731, a
dose escalation trial with 4 dosing arms. NN1731 and F1+2 plasma
concentrations were related to NN1731 doses to establish a population PK/PD model treating F1+2 as a PD biomarker.
A Population PK/PD Model Assessing the Pharmacodynamics of a Rapid-acting Recombinant FVIIa Analogue, NN1731, in Healthy Male Subjects .
Andreas Groth1, Judi Møss2, Tine Møller3, Steen H. Ingwersen1
1Biomodelling, 2Medical and Science, NovoSeven Key Projects, 3Biostatistics, Novo Nordisk A/S, Copenhagen, Denmark [email protected]
Results
Figure 3. Dose-independence check of PK model
Post-hoc parameter estimates of CL and V2 were checked for dose independence. Such a dependence appears to be absent for both parameters, indicating that the PK model is valid over the studied dose-range.
• Strategy:i. Develop PK-model from NN1731 plasma concentration data.
ii. Develop PD-model from individual post-hoc PK model parameters and F1+2 plasma concentration data.
• Data source: (3 pre- and 10 post-dose PK samples + 1 pre- and 5 post-dose PD samples) 6 healthy subjects 4 active (non-zero) dose levels. Dose range 5 µg/kg-30 µg/kg
• Modelling: PK and PD in man was modelled sequentially using NONMEM V with FOCE. Regarding inter-individual variability (i.i.v.) on model parameters, log-normal distributions were tested for significance against the hypotheses of zero i.i.v on that parameter (which is why the geometric, rather than the arithmetic, post-hoc estimate means are displayed on fig. 4).
Methods
Figure 4. Dose-independence check of PD model
Figure 1. Structure of PK/PD model
The resulting PK model was a standard two-compartment model with inter-individual variability (i.i.v.) on CL and V2. The PD model was a linear indirect response model withthe plasma concentration of NN1731 affecting the formation of F1+2 , incorporating i.i.v. on baseline F1+2 levels (B) and the efficacy parameter (E) . The F1+2 formation rate at the baseline state Cp=0 equals B kout .
F1+2
B kout (1+ E Cp)
koutCL
V1
V2
NN1731 dose
Q
Cp
NN1731 effect
0
50
100
150
5 10 15 20 25 30
DOSE
CL
Indv CL vs Dose
0
20
40
60
80
100
5 10 15 20 25 30
DOSE
V2
Indv V2 vs Dose
0.0
0.1
0.2
0.3
0.4
5 10 15 20 25 30
DOSE
EF
F
Indv EFF vs Dose
The individual post-hoc parameter estimates in the PD model were also checked for dependence on NN1731 dose. The result is less clear-cut than that of the PK parameters (fig. 3), but since the ranges of values for the lowest and the highest dose are quite similar for the efficacy parameter E, it is concluded that the NN1731 concentration-PD response relationship is well described.
0
50
100
150
200
5 10 15 20 25 30
DOSE
BA
S
Indv BAS vs Dose
o Individual post-hoc estimates
+ Geometric mean of individual post-hoc estimates
o Individual post-hoc estimates
+ Geometric mean of individual post-hoc estimates
Figure 2. Fit of PK/PD model
PK/PD model parameters
V1, V2: central & peripheral volumes of distribution, CL: clearance, Q: intercompartmental clearance, B: baseline F1+2 level, kout: rate constant for F1+2, E: NN1731 efficacyValues in parenthesis: Coefficients of Variation (CV’s) regarding i.i.v. for each parameter.
845
Time [h]
Co
nce
ntr
atio
n [
pM
]
0 5 10 15 20
10
02
00
30
04
00
1690
Time [h]
Co
nce
ntr
atio
n [
pM
]
0 5 10 15 20
10
02
00
30
04
00
3380
Time [h]
Co
nce
ntr
atio
n [
pM
]
0 5 10 15 20
10
02
00
30
04
00
5070
Time [h]
Co
nce
ntr
atio
n [
pM
]
0 5 10 15 20
10
02
00
30
04
00
845
Time [h]
Co
nce
ntr
atio
n [
pM
]
0 5 10 15 20
10
02
00
30
04
00
1690
Time [h]
Co
nce
ntr
atio
n [
pM
]
0 5 10 15 20
10
02
00
30
04
00
3380
Time [h]
Co
nce
ntr
atio
n [
pM
]
0 5 10 15 20
10
02
00
30
04
00
5070
Time [h]
Co
nce
ntr
atio
n [
pM
]
0 5 10 15 20
10
02
00
30
04
00
845
Time [h]
Co
nce
ntr
atio
n [
pM
]
0 5 10 15 20
10
02
00
30
04
00
1690
Time [h]
Co
nce
ntr
atio
n [
pM
]
0 5 10 15 20
10
02
00
30
04
00
3380
Time [h]
Co
nce
ntr
atio
n [
pM
]
0 5 10 15 20
10
02
00
30
04
00
5070
Time [h]
Co
nce
ntr
atio
n [
pM
]
0 5 10 15 20
10
02
00
30
04
00
845
Time [h]
Co
nce
ntr
atio
n [
pM
]
0 5 10 15 20
10
02
00
30
04
00
1690
Time [h]
Co
nce
ntr
atio
n [
pM
]
0 5 10 15 20
10
02
00
30
04
00
3380
Time [h]
Co
nce
ntr
atio
n [
pM
]
0 5 10 15 20
10
02
00
30
04
00
5070
Time [h]
Co
nce
ntr
atio
n [
pM
]
0 5 10 15 20
10
02
00
30
04
00
The PK/PD model predictions of the F1+2 time profiles for each trial subject as well as for the typical subject are shown along with the observations and their means for each dose level.
, ,.. Model predictions
(individual)
Model predictions (typical
subject)
o,o,.. Observations
+ Mean of observations at time
point
5 g/kg 10 g/kg
20 g/kg 30 g/kg
References1 E. Persson et al, Proc Natl Acad Sci U S A, 96;13583,2001
NN1731 dose(µg/kg)
NN1731 dose(µg/kg)
NN1731 dose(µg/kg)
NN1731 dose(µg/kg)
E
pM
/h/(
IU/m
l)
V2 (m
l/kg
)
CL m
l/kg
//h
B (
pM
)
Model parameter V1 V2 CL Q B kout E
Unit ml/kg ml/kg ml/kg/h ml/kg/h pM 1/h pM/h/IU/ml)
Estimate 59.6 78.0 (14%) 120 (14%) 38.6 132 (29%) 0.346 0.164 (46%)
S.E. of estimate 2.2 4.0 4.5 2.0 11 0.048 0.042
A sketch of the pro-coagulatory actions of thrombin, also known as coagulation factor IIa. Thrombin activates several coagulatory proteins and these actions cascade down eventually leading to the formation of cross-linked fibrin (CLIa) which forms the actual blood clot.